华康洁净 reported revenue of ¥1.02B for the period ended 2026-06-30, +22.6% year on year. Net income was ¥0.01B, a 1.5% net margin on a 28.5% gross margin. The largest revenue line is 净化系统集成业务 at 81% of the total. Free cash flow for the period was ¥-0.15B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥1.02B | +22.6% |
| Gross profit | ¥0.29B | — |
| Operating income | ¥0.02B | — |
| Net income | ¥0.01B | -25.5% |
| Gross margin | 28.5% | Net margin 1.5% |
| Revenue Q/Q | +52.4% | — |
| Segment | Revenue | Share |
|---|---|---|
| 净化系统集成业务 | ¥0.83B | 80.9% |
| 医疗耗材销售 | ¥0.09B | 8.6% |
| 医疗设备销售 | ¥0.08B | 7.6% |
| 运维服务 | ¥0.02B | 2.4% |
| 其他(补充) | ¥0.01B | 0.6% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.73B | 71.5% |
| R&D | ¥0.04B | 4.3% |
| SG&A | ¥0.21B | 20.9% |
| Tax & other | ¥0.00B | 0.4% |
| Item | Amount |
|---|---|
| Total assets | ¥4.54B |
| Total liabilities | ¥2.59B |
| Shareholders' equity | ¥1.95B |
| Equity / assets | 43.0% |
| Operating cash flow | ¥-0.14B |
| Capital expenditure | ¥0.01B |
| Free cash flow | ¥-0.15B |
| Cash conversion (OCF / net income) | -2590% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
和顺科技 ・ 瑞泰新材 ・ 普瑞眼科 ・ 宏源药业 ・ 杰创智能 ・ 威尔高 ・ 同星科技 ・ 通力科技 ・ 华融化学 ・ 普蕊斯 ・ 富士莱 ・ 艾布鲁
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies